Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $55.50.

TVRD has been the topic of several research reports. Wall Street Zen cut Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings restated a “sell (e)” rating on shares of Tvardi Therapeutics in a research note on Monday, December 29th. Finally, Lucid Cap Mkts upgraded Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th.

Tvardi Therapeutics Trading Down 1.5%

Shares of TVRD opened at $3.99 on Monday. Tvardi Therapeutics has a 1-year low of $3.50 and a 1-year high of $43.65. The firm’s 50-day moving average price is $4.08 and its 200-day moving average price is $12.95. The firm has a market capitalization of $37.43 million, a price-to-earnings ratio of -0.41 and a beta of 0.13.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of TVRD. JPMorgan Chase & Co. bought a new stake in Tvardi Therapeutics during the second quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Tvardi Therapeutics during the second quarter valued at approximately $43,000. Headlands Technologies LLC purchased a new position in shares of Tvardi Therapeutics during the second quarter valued at approximately $80,000. New York State Common Retirement Fund purchased a new stake in shares of Tvardi Therapeutics in the 2nd quarter worth approximately $92,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Tvardi Therapeutics in the 3rd quarter worth approximately $318,000. 44.66% of the stock is owned by hedge funds and other institutional investors.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.